Towards curative therapy in gastric cancer: Faraway, so close!

Table 4 Selected randomized controlled trials studying the extent of the lymph node dissection for patients with gastric cancer

Ref.	Year published	Region	Extent of Lymph node dissection	Patients(n)	Morbidity	Mortality	5 yr overall survival (%)
Dent et al[62]	1988	South Africa	D1	22	22%	0%	N/A
			D2	21	43%	0%	N/A
BonenKamp et al[59,66]	1995	The Netherlands	D1	380	25%	4%	45
			D2	331	43%	10%	47
Cuschieri et al[60,65]	1996	Europe	D1	200	28%	6.5%	35
			D2	200	46%	13%	33
Wu et al[63,64]	2004	Taiwan	D1	110	7.3%	0%	53.6
			D3	111	17.1%	0%	59.5
Sasako et al[69]	2008	Japan	D2	263	20.9%	0.8%	69.2
			D2 + PAND	260	28.1%	0.8%	70.3
Degiuli et al[67,68]	2010	Italy	D1	133	12%	3%	66.5
			D2	134	17.9%	2.2%	64.2

PAND: Para-aortic node dissection.